Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses
**Background:** Studies have shown that improvements in glycemic control are associated with avoidance or delayed onset of diabetes complications, improvements in health-related quality of life, and reductions in diabetes-related health care costs. Clinical practice guidelines recommend maintaining...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2018-02-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/9783 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860256584761344 |
|---|---|
| author | John E. Schneider Anjani Parikh Ivana Stojanovic |
| author_facet | John E. Schneider Anjani Parikh Ivana Stojanovic |
| author_sort | John E. Schneider |
| collection | DOAJ |
| description | **Background:** Studies have shown that improvements in glycemic control are associated with avoidance or delayed onset of diabetes complications, improvements in health-related quality of life, and reductions in diabetes-related health care costs. Clinical practice guidelines recommend maintaining a hemoglobin A1c (HbA1c) level less than 7%, but among type 2 diabetes patients using insulin, two-thirds have HbA1c above 7% and one-third have HbA1c above 9%.
**Objectives:** This study examined the use of insulin management services to enable patients to optimize insulin dosing to achieve HbA1c targets and subsequently reduce health care costs. Cost savings may be achieved through reduced complications and hospitalizations, as well as reduced outpatient, physician, and clinic costs. This study quantified the reduction in pharmaceutical expenses related to the use of an enhanced insulin management service to improve glycemic control.
**Methods:** Two hundred seventeen insulin-reliant patients were enrolled in the d-Nav® Insulin Guidance Service through a participating insurance group. A prospective cost analysis was conducted using data from enrolled patients who completed the first 90 days of follow up.
**Results:** Of the 192 patients who completed the 90-day study period, 54 (28.13%) were prescribed one or more expensive medications at baseline, but 45 (83.33%) of those patients were eligible for medication discontinuation after 90 days. At baseline, the annual cost of expensive medications per patient was $7564 (CI: $5191-$9938) and $1483 (CI: -$1463-$4429) at 90 days (p<0.001). Direct savings from medication elimination was estimated to be $145 per patient per month (PPPM) or $1736 per patient per year (PPPY) for all patients and $514 PPPM/$6172 PPPY for the target group. Patients that completed the 90-day period significantly reduced HbA1c levels from 9.37% (CI:7.72%-11.03%) at baseline to 7.71% (CI: 6.70%-8.73%) (p<0.001). A total of 170 (88.54%) patients had improved HbA1c at 90 days.
**Conclusions:** Use of the insulin guidance service achieved improved glycemic control by optimizing insulin dosing, which enabled most patients using the service to reduce or eliminate the use of expensive diabetes medications. Further study is needed to assess the impact of optimized insulin dosing on other diabetes related health care costs in a usual practice setting. |
| format | Article |
| id | doaj-art-16300b572f4445ecbb7f72ecfd5df729 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2018-02-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-16300b572f4445ecbb7f72ecfd5df7292025-02-10T16:13:14ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362018-02-0161Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical ExpensesJohn E. SchneiderAnjani ParikhIvana Stojanovic**Background:** Studies have shown that improvements in glycemic control are associated with avoidance or delayed onset of diabetes complications, improvements in health-related quality of life, and reductions in diabetes-related health care costs. Clinical practice guidelines recommend maintaining a hemoglobin A1c (HbA1c) level less than 7%, but among type 2 diabetes patients using insulin, two-thirds have HbA1c above 7% and one-third have HbA1c above 9%. **Objectives:** This study examined the use of insulin management services to enable patients to optimize insulin dosing to achieve HbA1c targets and subsequently reduce health care costs. Cost savings may be achieved through reduced complications and hospitalizations, as well as reduced outpatient, physician, and clinic costs. This study quantified the reduction in pharmaceutical expenses related to the use of an enhanced insulin management service to improve glycemic control. **Methods:** Two hundred seventeen insulin-reliant patients were enrolled in the d-Nav® Insulin Guidance Service through a participating insurance group. A prospective cost analysis was conducted using data from enrolled patients who completed the first 90 days of follow up. **Results:** Of the 192 patients who completed the 90-day study period, 54 (28.13%) were prescribed one or more expensive medications at baseline, but 45 (83.33%) of those patients were eligible for medication discontinuation after 90 days. At baseline, the annual cost of expensive medications per patient was $7564 (CI: $5191-$9938) and $1483 (CI: -$1463-$4429) at 90 days (p<0.001). Direct savings from medication elimination was estimated to be $145 per patient per month (PPPM) or $1736 per patient per year (PPPY) for all patients and $514 PPPM/$6172 PPPY for the target group. Patients that completed the 90-day period significantly reduced HbA1c levels from 9.37% (CI:7.72%-11.03%) at baseline to 7.71% (CI: 6.70%-8.73%) (p<0.001). A total of 170 (88.54%) patients had improved HbA1c at 90 days. **Conclusions:** Use of the insulin guidance service achieved improved glycemic control by optimizing insulin dosing, which enabled most patients using the service to reduce or eliminate the use of expensive diabetes medications. Further study is needed to assess the impact of optimized insulin dosing on other diabetes related health care costs in a usual practice setting.https://doi.org/10.36469/9783 |
| spellingShingle | John E. Schneider Anjani Parikh Ivana Stojanovic Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses Journal of Health Economics and Outcomes Research |
| title | Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses |
| title_full | Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses |
| title_fullStr | Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses |
| title_full_unstemmed | Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses |
| title_short | Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses |
| title_sort | impact of a novel insulin management service on non insulin pharmaceutical expenses |
| url | https://doi.org/10.36469/9783 |
| work_keys_str_mv | AT johneschneider impactofanovelinsulinmanagementserviceonnoninsulinpharmaceuticalexpenses AT anjaniparikh impactofanovelinsulinmanagementserviceonnoninsulinpharmaceuticalexpenses AT ivanastojanovic impactofanovelinsulinmanagementserviceonnoninsulinpharmaceuticalexpenses |